Lyell Wealth Management LP Trims Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Lyell Wealth Management LP trimmed its position in Zoetis Inc. (NYSE:ZTS) by 0.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 66,971 shares of the company’s stock after selling 81 shares during the period. Lyell Wealth Management LP’s holdings in Zoetis were worth $10,912,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ZTS. Atlantic Edge Private Wealth Management LLC boosted its holdings in Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 140 shares in the last quarter. Darwin Wealth Management LLC bought a new stake in Zoetis in the third quarter worth $31,000. First Personal Financial Services bought a new stake in Zoetis in the third quarter worth $33,000. Capital Performance Advisors LLP bought a new stake in Zoetis in the third quarter worth $33,000. Finally, Dunhill Financial LLC boosted its holdings in Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Down 0.7 %

ZTS stock opened at $156.43 on Wednesday. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The business’s 50-day moving average is $167.70 and its two-hundred day moving average is $178.44. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The company has a market cap of $70.05 billion, a price-to-earnings ratio of 28.60, a P/E/G ratio of 2.71 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. As a group, analysts forecast that Zoetis Inc. will post 6.06 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.28%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is 36.56%.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ZTS shares. Morgan Stanley dropped their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Stifel Nicolaus lowered their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Piper Sandler lowered their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Finally, UBS Group began coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and an average price target of $214.90.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.